Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-101556143 in Metastatic Androgen Pathway Modulation-Resistant Prostate Cancer
NCT07906717Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2026
- Primary completion
- Feb 2028
- Countries
- 2
01
Overview
A Phase 3 trial of JNJ-101556143 in prostate cancer (PCa), sponsored by Janssen Pharmaceutical. Started Oct 2026; status: recruiting.
02
Drugs
JNJ-101556143
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07906717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07906717.